A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine

por Dart, Chiara R., Mukherjee, Nabanita, Amato, Carol M., Goulding, Anabel, MacBeth, Morgan, Van Gulick, Robert, Couts, Kasey L., Lambert, James R., Norris, David A., Robinson, William A., Shellman, Yiqun G.
Publicado 2021

Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma

por Mukherjee, Nabanita, Amato, Carol M., Skees, Jenette, Todd, Kaleb J., Lambert, Karoline A., Robinson, William A., Van Gulick, Robert, Weight, Ryan M., Dart, Chiara R., Tobin, Richard P., McCarter, Martin D., Fujita, Mayumi, Norris, David A., Shellman, Yiqun G.
Publicado 2020

MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells

por Mukherjee, Nabanita, Skees, Jenette, Todd, Kaleb J., West, Drake A., Lambert, Karoline A., Robinson, William A., Amato, Carol M., Couts, Kasey L., Van Gullick, Robert, MacBeth, Morgan, Nassar, Kelsey, Tan, Aik-Choon, Zhai, Zili, Fujita, Mayumi, Bagby, Stacey M., Dart, Chiara R., Lambert, James R., Norris, David A., Shellman, Yiqun G.
Publicado 2020